Completion of the divestment of Aspen’s Nutritionals business to Lactalis ASPEN PHARMACARE HOLDINGS LIMITED (Incorporated in the Republic of South Africa) (“Aspen Holdings”) Registration number: 1985/0002935/06 Share code: APN ISIN: ZAE000066692 and its subsidiaries (collectively “Aspen” or “the Group”) COMPLETION OF THE DIVESTMENT OF ASPEN’S NUTRITIONALS BUSINESS TO LACTALIS With reference to previous announcements to shareholders in respect of this transaction, Aspen is pleased to confirm that it completed the divestment of its Nutritionals Business to the Lactalis Group for a gross consideration of EUR 740 million on 31 May 2019. Aspen can also confirm that it has received proof of payment of the gross consideration from the Lactalis Group and expects all of the funds to be in its bank accounts within the next few days. The estimated net cash inflows from the transaction, after payment of transaction related taxes, the buy-out of minority shareholders and the payment of transaction costs, will be approximately EUR 635 million and the financial effects remain in line with Aspen’s expectations. The completion of this divestment and the divestment of a portfolio of products in Australia to Mylan, announced on 20 May 2019, are important steps towards achieving one of Aspen’s stated priorities, namely the deleveraging of its balance sheet. Durban 3 June 2019 Sponsor Investec Bank Limited Date: 03/06/2019 08:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on, information disseminated through SENS.